Haemoperfusion should only be used for COVID-19 in the context of randomized trials

Interest in the use of haemoperfusion for severe COVID-19 has been spurred by anecdotal reports of its efficacy and expert reviews suggesting theoretical benefits. However, on the basis of the limited current evidence, haemoperfusion remains an experimental therapy that should only be applied within...

Descripción completa

Detalles Bibliográficos
Autores principales: Clark, Edward G., Hiremath, Swapnil, McIntyre, Lauralyn, Wald, Ron, Hundemer, Gregory L., Joannidis, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478103/
https://www.ncbi.nlm.nih.gov/pubmed/32901129
http://dx.doi.org/10.1038/s41581-020-00352-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478103/
https://www.ncbi.nlm.nih.gov/pubmed/32901129
http://dx.doi.org/10.1038/s41581-020-00352-9

Ejemplares similares